In September 2025, Germany stopped approving new medical cannabis import permits. No supplier had failed an audit. No batch had been rejected. The country had simply imported the full volume it told the United Nations it would need that year, and the approval queue froze until that number was revised.
A cannabis import quota is the annual quantity a country reports to the International Narcotics Control Board as its expected requirement, filed under the Single Convention on Narcotic Drugs. Once actual imports reach that figure, national regulators stop issuing new import authorisations until the government files a supplementary estimate and the Board confirms it.
That ceiling sits outside your control and outside your buyer's control. It still decides whether your next pallet moves in October or in January. Two of the largest medical markets hit their limits in the same quarter of 2025, and they moved in opposite directions.
How the estimates system sets national import ceilings
Cannabis is still a Schedule I narcotic drug under the 1961 treaty. Every country that imports it works inside the estimates system. Governments file an annual estimate of national requirements, normally by the end of June for the following calendar year. Article 21 then limits what a country may import and manufacture to the figure it filed. Article 31 adds the transactional layer: each individual shipment needs an import authorisation in the destination market and a matching export authorisation in the country of origin.
Why quota is the wrong word
The industry calls these numbers quotas. Technically they are estimates. The Board does not allocate volume to countries and it does not cap global medical cannabis production. It confirms figures that governments submit, publishes them, and tracks real trade against them. When imports run past the estimate, the Board asks the government to account for the gap. Sometimes the answer is that part of the volume was always destined for re-export. Sometimes it is a supplementary estimate, filed to cover the rest of the year.
That distinction matters commercially. A quota implies a fixed pie and a race for share. An estimate implies a forecast a national regulator can correct. So the useful question is never how large the ceiling is. It is how accurate the forecast was, and how quickly the regulator can fix it.
Where Canadian exporters sit in the chain
You feel this at one remove. Health Canada issues an export permit under the Cannabis Act against the importing country's authorisation. If your buyer cannot obtain an import permit because the national estimate is spent, your Canadian application has nothing to attach to. The paperwork you control is fine. The paperwork you depend on has stopped. Our walkthrough of the Health Canada export permit process maps that document chain step by step.
What Germany's 2025 ceiling taught Canadian exporters
Germany's 2025 estimate was 122 tonnes. Imports reached it by mid-September, and BfArM stopped approving new applications. The agency was careful with its framing. This was not an import ban. Permits already issued stayed valid and scheduled deliveries went ahead. New approvals simply queued.
BfArM also explained why the original figure had been cautious. Under the treaty, estimates are meant to be set restrictively, and a government that inflates its stated requirement risks having the Board cut it. National regulators are therefore biased toward under-forecasting, which is exactly the wrong instinct for a market growing as fast as Germany's.
The correction arrived on 20 October 2025, when the confirmed ceiling rose to roughly 192.5 tonnes and approvals resumed. Even the revised number was overtaken. Full-year 2025 imports came in near 201 tonnes. The first quarter of 2026 brought another 50,539 kg into the country, of which 26,753 kg, about 53 percent, came from Canada.
Read that sequence from a supply planning seat and one lesson stands out. Your German partner's remaining allocation behaves like a lead time, and hardly anyone tracks it as one. Meeting the German import requirements gets you qualified. Remaining permitted volume is what actually schedules the truck. Buyers evaluating a Canadian partner for the medical channel can review how we structure international supply before a ceiling reopens.
Why Australia's estimate moved the opposite way
Australia spent the same autumn heading in the other direction. In October 2025 the Board reduced the country's 2025 figure from 101 tonnes to 88 tonnes, citing imports well below what industry had forecast. The Office of Drug Control had collected import applications totalling roughly 150 tonnes for the year, while actual volume landed near half of that. Permits were issued and never used.
Unused permits are not harmless. They reserve headroom inside the national estimate and slow approvals for companies that do intend to ship. The regulator's answer was to make forecasting accuracy expensive. An importer that failed to bring in at least 75 percent of its approved 2025 volume would see its 2026 forecast cut to match real imports. Repeat offenders face caps on future allocations. By early 2026 the ODC confirmed that 89 percent of importers had their forecasts adjusted.
| Market | 2025 opening estimate | Revision | Cause | Effect on exporters |
|---|---|---|---|---|
| Germany | 122 tonnes | Raised to about 192.5 tonnes, 20 October | Demand outran a restrictive forecast | Roughly five weeks of paused approvals, then a rush |
| Australia | 101 tonnes | Cut to 88 tonnes, October | Forecast volume went unused | Slower processing, tighter 2026 allocations |
For a Canadian LP, the Australian correction shifts buyer behaviour in a useful direction. Importers now have a financial reason to order what they can genuinely move, which means firmer purchase orders and fewer speculative reservations. It also raises the cost of a supplier who misses a shipping window, because an unused permit is now a debt against next year's allocation. The permit and product standard requirements underneath all of this sit in our Australian export guide.
How to plan shipments around the quota calendar
None of this is controllable from Montreal. All of it is forecastable. Four checks turn ceiling risk from a surprise into a scheduling input.
The 4-point quota readiness check
- Ask for remaining allocation, not just the purchase order. Request the import authorisation number, the permitted quantity and the expiry date before you commit cultivation capacity to a buyer.
- Track the mid-year estimate deadline. Governments file next-year figures around the end of June. The demand signals your partners send in the second quarter shape what they will be permitted to buy for all of the following year.
- Treat the fourth quarter as the risk window. Both 2025 corrections landed there, because that is when a full year of real trade finally meets a forecast written eighteen months earlier.
- Keep the export file current year-round. When a ceiling reopens, permits move fast, and the exporters who ship first are the ones whose certificate of analysis data, packaging records and batch documentation are already assembled.
Destination diversification does the rest of the work. An LP shipping into one market inherits that country's forecasting accuracy as its own commercial risk. An LP qualified in three can move volume toward whichever ceiling has room this quarter, which is a far cheaper hedge than holding finished inventory through a freeze.
AlphaLeaf is a Health Canada Licensed Producer in Montreal growing indoor, hand-trimmed flower from refined genetics, with ISO/IEC 17025 batch testing and full lot traceability behind every shipment. We hold export authorisation under the Cannabis Act and keep the compliance documentation that German, Australian and Israeli import partners have to file the moment their national ceiling reopens.
If you are planning volume for the back half of 2026 and want a supply partner whose file is ready before your permit is, talk to our export team.
Frequently Asked Questions
Is the INCB cannabis quota a global production limit?
No. Individual governments submit their own estimates of national requirements, and the Board confirms, publishes and monitors those figures. There is no worldwide cap on medical cannabis production or on how much any producer may cultivate.
What happens when a country reaches its cannabis import estimate?
The national regulator stops issuing new import authorisations. Permits already granted normally stay valid and scheduled deliveries continue. New approvals resume once the government files a supplementary estimate and the Board confirms the higher figure.
How long does a supplementary estimate take to confirm?
It varies by country and by how quickly the national regulator files. Germany's 2025 pause ran from mid-September to 20 October, roughly five weeks from the freeze to resumed approvals.
Does a foreign import ceiling affect a Health Canada export permit?
Yes, indirectly. A Canadian export permit is issued against the importing country's import authorisation. If your buyer cannot obtain that authorisation because the national estimate is exhausted, the Canadian permit cannot be completed either.
How should a Canadian LP verify a buyer's remaining allocation?
Ask for the import authorisation number, the permitted quantity and the expiry date before confirming production. A buyer operating inside a constrained national ceiling should be able to produce those details on request.
